Patents by Inventor Rachel Moodie

Rachel Moodie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of treating Crohn's disease and ulcerative colitis by using an induction dosing regimen of adalimumab
    Patent number: 10689440
    Abstract: The invention relates to a multiple-variable dose method for treating a disorder in which TNF? activity is detrimental, comprising administering to a subject in need thereof a first induction dose of an anti-TNF? antibody which ranges from 161 to 320 mg such that a threshold level of TNF? inhibitor is achieved within an induction phase; and subsequently administering to the subject at least one treatment dose of the TNF? inhibitor within a treatment phase, such that treatment occurs.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: June 23, 2020
    Assignee: Fresenius Kabi Deutschland GmbH
    Inventors: Rachel Moodie, Elizabeth Hyland
  • Method of treating a tumor necrosis factor ? (TNF?)-related disorder by using an induction dosing regimen of adalimumab
    Patent number: 10669333
    Abstract: The invention relates to a multiple-variable dose method for treating a disorder in which TNF? activity is detrimental, comprising administering to a subject in need thereof a first induction dose of an anti-TNF? antibody which ranges from 161 to 320 mg such that a threshold level of TNF? inhibitor is achieved within an induction phase; and subsequently administering to the subject at least one treatment dose of the TNF? inhibitor within a treatment phase, such that treatment occurs.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: June 2, 2020
    Assignee: Fresenius Kabi Deutschland GmbH
    Inventors: Rachel Moodie, Elizabeth Hyland
  • Methods of treating Crohn's disease or ulcerative colitis using an induction dosing regimen comprising anti-TNF-alpha antibody
    Patent number: 10179811
    Abstract: The invention relates to a multiple-variable dose method for treating a disorder in which TNF? activity is detrimental, comprising administering to a subject in need thereof a first induction dose of an anti-TNF? antibody which ranges from 161 to 320 mg such that a threshold level of TNF? inhibitor is achieved within an induction phase; and subsequently administering to the subject at least one treatment dose of the TNF? inhibitor within a treatment phase, such that treatment occurs.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: January 15, 2019
    Assignee: Fresenius Kabi Deutschland GmbH
    Inventors: Rachel Moodie, Elizabeth Hyland
  • INDUCTION DOSING REGIMEN
    Publication number: 20180291092
    Abstract: The invention relates to a multiple-variable dose method for treating a disorder in which TNF? activity is detrimental, comprising administering to a subject in need thereof a first induction dose of an anti-TNF? antibody which ranges from 161 to 320 mg such that a threshold level of TNF? inhibitor is achieved within an induction phase; and subsequently administering to the subject at least one treatment dose of the TNF? inhibitor within a treatment phase, such that treatment occurs
    Type: Application
    Filed: June 21, 2018
    Publication date: October 11, 2018
    Inventors: Rachel Moodie, Elizabeth Hyland
  • INDUCTION DOSING REGIMEN
    Publication number: 20180291091
    Abstract: The invention relates to a multiple-variable dose method for treating a disorder in which TNF? activity is detrimental, comprising administering to a subject in need thereof a first induction dose of an anti-TNF? antibody which ranges from 161 to 320 mg such that a threshold level of TNF? inhibitor is achieved within an induction phase; and subsequently administering to the subject at least one treatment dose of the TNF? inhibitor within a treatment phase, such that treatment occurs
    Type: Application
    Filed: June 21, 2018
    Publication date: October 11, 2018
    Applicant: Fresenius Kabi Deutschland GmbH
    Inventors: Rachel Moodie, Elizabeth Hyland
  • INDUCTION DOSING REGIMEN
    Publication number: 20180066048
    Abstract: The invention relates to a multiple-variable dose method for treating a disorder in which TNF? activity is detrimental, comprising administering to a subject in need thereof a first induction dose of an anti-TNF? antibody which ranges from 161 to 320 mg such that a threshold level of TNF? inhibitor is achieved within an induction phase; and subsequently administering to the subject at least one treatment dose of the TNF? inhibitor within a treatment phase, such that treatment occurs
    Type: Application
    Filed: April 8, 2016
    Publication date: March 8, 2018
    Inventors: Rachel Moodie, Elizabeth Hyland